成功 (選択、安全性、有効性、健康経済学およびプロムス) PTA 調査 (SUCCESS PTA)
Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).
調査の概要
状態
条件
詳細な説明
Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).
This study will capture data from the use of the SELUTION SLR according to its approved labelling. Each indication for use will have a specific data sets in addition to generic data sets that are common across all indications.
Patients will be followed for 5 years post-procedure to obtain safety and efficacy data. A health economic analysis will be made comparing data between countries within the study and to published data for existing treatment options. Generic and disease specific Patient Reported Outcome Measures (PROMs) will be used to measure the impact of the intervention on the overall health status of patients.
Imaging data collection for patients whose standard of care includes imaging follow-up will be captured and analysed.
Data will be collected from any subject who receives a CE marked device for treatment of a peripheral (i.e. non-cardiovascular) vascular lesion.
Data analysis will be stratified by lesion location.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
La Plata、アルゼンチン
- Hospital Italiano La Plata
-
-
-
-
-
Frimley、イギリス
- Frimley Park Hospital
-
Leicester、イギリス
- University Hospitals of Leicester NHS Trust
-
London、イギリス
- Barts Health NHS Trust (ROYAL HOSPITAL LONDON)
-
London、イギリス
- Guy's & St Thomas Hospital
-
Redhill、イギリス
- East Surrey Hospital
-
-
-
-
-
Tilburg、オランダ
- Elisabeth - TweeSteden Ziekenhuis
-
-
-
-
-
Athens、ギリシャ
- Attikon University Hospital
-
Athens、ギリシャ
- Athens Medical Center
-
Pátrai、ギリシャ
- General University Hospital of Patras
-
-
-
-
-
Singapore、シンガポール
- National University Hospital Singapore (NUHS)
-
-
-
-
-
Aarau、スイス
- Kantonsspital Aarau
-
Geneva、スイス
- Hôpitaux Universitaires de Genève (HUG)
-
Lucerne、スイス
- Luzerner Kantonsspital
-
-
-
-
-
Trnava、スロバキア
- Trnava University Hospital
-
-
-
-
-
Arnsberg、ドイツ
- Klinikum Hochsauerland
-
Bad Krozingen、ドイツ
- Universitätsklinikum Freiburg
-
Buchholz、ドイツ
- Krankenhaus Buchholz
-
Essen、ドイツ
- Universitätsklinikum Essen
-
Flensburg、ドイツ
- DIAKO Krankenhaus
-
Hamburg、ドイツ
- Medizinisches Versorgungszentrum
-
Heidelberg、ドイツ
- Universitätsklinikum Heidelberg
-
Langensteinbach、ドイツ
- SRH Klinikum Karlsbad - Langensteinbach
-
München、ドイツ
- LMU Klinikum Campus Großhadern
-
Tübingen、ドイツ
- Universitätsklinikum Tübingen
-
Weinheim、ドイツ
- Grn Klinik Weinheim
-
Würzburg、ドイツ
- Universitätsklinikum Würzburg
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Subject age is ≥ 18 years
- Subject is able and willing to provide informed consent
- Subject is suitable for treatment with a MedAlliance SELUTION SLR DEB according to the current Instruction for use.
Exclusion Criteria:
- In the opinion of the treating investigator the subject has a life expectancy of less than 12 months
- In the opinion of the treating investigator the subject is unlikely to comply with the study follow-up regime
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:SELUTION SLR™ DEB
Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter. |
This study will capture data from the use of the SELUTION SLR according to its approved labelling. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinically Driven Target Lesion Revascularization
時間枠:1 year after treatment
|
The primary endpoint will be freedom from Clinically Driven Target Lesion Revascularisation (CD-TLR) at 1-year post-intervention. |
1 year after treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Device Success
時間枠:At end of procedure
|
Successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure. |
At end of procedure
|
|
Procedure success
時間枠:At end of procedure
|
Device success and residual stenosis ≤50% at the end of the procedure. |
At end of procedure
|
|
Clinical success
時間枠:At discharge after procedure
|
Procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion or TLR) prior to discharge. |
At discharge after procedure
|
|
Major Adverse Limb Events (MALE) composite endpoint
時間枠:At discharge after procedure and 1, 6, 12, 24, 36, 48 and 60 months
|
Severe limb ischemia leading to an intervention or major vascular amputation (above the ankle). |
At discharge after procedure and 1, 6, 12, 24, 36, 48 and 60 months
|
|
Major Cardiac Events Major Cardiac Events
時間枠:At 1, 6, 12, 24, 36,48, 60 months
|
MI, Stroke, Cardiovascular death |
At 1, 6, 12, 24, 36,48, 60 months
|
|
Death
時間枠:At 1, 6, 12, 24, 36, 48, 60 months
|
All-cause, cardiac, device related, procedure related |
At 1, 6, 12, 24, 36, 48, 60 months
|
|
TLR
時間枠:At 1, 6, 12, 24, 36, 48, 60 months
|
Number of Target Lesion Revascularizations |
At 1, 6, 12, 24, 36, 48, 60 months
|
|
TVR
時間枠:At 1, 6, 12, 24, 36, 48, 60 months
|
Number of Target Vessel Revascularizations |
At 1, 6, 12, 24, 36, 48, 60 months
|
|
Time to first CD-TLR
時間枠:up to 60 months
|
Time to first Clinically Driven Target Lesion Revascularization |
up to 60 months
|
|
Target limb revascularization
時間枠:At 1, 6, 12, 24, 36, 48, 60 months
|
Number of Target limb revascularizations |
At 1, 6, 12, 24, 36, 48, 60 months
|
|
Thrombosis at the target site
時間枠:At 1 month
|
Number of Thrombosis at the target site |
At 1 month
|
|
Amputation
時間枠:up to 60 months
|
Number of Amputations |
up to 60 months
|
|
Rutherford Classification score
時間枠:At 6, 12, 24, 36, 48, 60 months
|
Change in Rutherford Classification score from baseline (Scale from 0 to 6, higher score means worse outcome. |
At 6, 12, 24, 36, 48, 60 months
|
|
Ankle Brachial Index (ABI)
時間枠:At 6, 12 months only
|
Change in ankle brachial index (ABI) from baseline |
At 6, 12 months only
|
|
Pedal pulse
時間枠:6, 12 months only
|
Presence of Pedal pulse |
6, 12 months only
|
|
Wound status if applicable
時間枠:6, 12 months only
|
location, size, infection, status, Wound, Ischemia and Foot Infection (WIfI) classification system score |
6, 12 months only
|
|
Kawarada Classification score
時間枠:At end of procedure
|
Change from baseline to end of procedure to assess change in severity of Pedal Artery Disease |
At end of procedure
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。